Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pazopanib: a novel multitargeted tyrosine kinase inhibitor.

Literature DB >> 17288876

Pazopanib: a novel multitargeted tyrosine kinase inhibitor.

Abstract

Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. Preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2007 PMID： 17288876 DOI： 10.1007/s11912-007-0007-2

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

17 in total

Review 1. Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents.

Authors: George D Hartman; Mark E Fraley; Mark T Bilodeau
Journal: Expert Opin Investig Drugs Date: 2002-06 Impact factor: 6.206

Review 2. Vascular-specific growth factors and blood vessel formation.

Authors: G D Yancopoulos; S Davis; N W Gale; J S Rudge; S J Wiegand; J Holash
Journal: Nature Date: 2000-09-14 Impact factor: 49.962

Review 3. Signal transduction by receptors with tyrosine kinase activity.

Authors: A Ullrich; J Schlessinger
Journal: Cell Date: 1990-04-20 Impact factor: 41.582

4. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Authors: P Lindahl; B R Johansson; P Levéen; C Betsholtz
Journal: Science Date: 1997-07-11 Impact factor: 47.728

Review 5. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.

Authors: Paul A Renhowe
Journal: Curr Opin Drug Discov Devel Date: 2002-03

Review 6. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

Authors: Brian I Rini; Eric J Small
Journal: J Clin Oncol Date: 2004-11-08 Impact factor: 44.544

Review 7. Protein tyrosine kinase structure and function.

Authors: S R Hubbard; J H Till
Journal: Annu Rev Biochem Date: 2000 Impact factor: 23.643

8. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors: L Holmgren; M S O'Reilly; J Folkman
Journal: Nat Med Date: 1995-02 Impact factor: 53.440

9. Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?

Authors: Carlos L Arteaga
Journal: Clin Cancer Res Date: 2003-04 Impact factor: 12.531

10. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312

44 in total

Review 1. Targeted therapies for non-small cell lung cancer: an evolving landscape.

Authors: Sumanta Kumar Pal; Robert A Figlin; Karen Reckamp
Journal: Mol Cancer Ther Date: 2010-06-22 Impact factor: 6.261

Review 2. Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.

Authors: Consuelo Buttigliero; Valentina Bertaglia; Silvia Novello
Journal: Transl Lung Cancer Res Date: 2016-12

3. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.

Authors: Elisabeth I Heath; Karen Forman; Lisa Malburg; Shelby Gainer; A Benjamin Suttle; Laurel Adams; Howard Ball; Patricia LoRusso
Journal: Invest New Drugs Date: 2011-08-03 Impact factor: 3.850

Review 4. Concise drug review: pazopanib and axitinib.

Authors: Robin M J M van Geel; Jos H Beijnen; Jan H M Schellens
Journal: Oncologist Date: 2012-06-25

5. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.

Authors: Sara K Taylor; Stephen Chia; Susan Dent; Mark Clemons; Mark Agulnik; Pamela Grenci; Lisa Wang; Amit M Oza; Percy Ivy; Kathleen I Pritchard; Natasha B Leighl
Journal: Oncologist Date: 2010-08-03

6. An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

Authors: Joanne Brady; Pippa Corrie; Ian Chau; Raghunadharao Digumarti; Laurel M Adams; Jeffrey Botbyl; Kevin H Laubscher; Rachel S Midgley; Mohandas Mallath
Journal: Invest New Drugs Date: 2013-02-28 Impact factor: 3.850

Review 10. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.

Authors: M Majem; C Pallarès
Journal: Clin Transl Oncol Date: 2013-01-29 Impact factor: 3.405